Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
46.28 SEK | -0.34% |
|
+9.00% | +76.64% |
06-27 | Hansa Biopharma AB Announces Board Appointments | CI |
05-31 | Hansa Biopharma Finalizes Patient Randomization for Use of Imlifidase inKidney Transplantation Trial | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+76.64% | 296M | |
+19.41% | 45.51B | |
+38.65% | 39.36B | |
-8.62% | 38.52B | |
+26.95% | 30.74B | |
-13.50% | 26.03B | |
+10.74% | 25.92B | |
+44.87% | 14.13B | |
+34.36% | 12.73B | |
-7.14% | 11.29B |
- Stock Market
- Equities
- HNSA Stock
- News Hansa Biopharma AB
- Transcript : Hansa Biopharma AB, Nine Months 2021 Earnings Call, Oct 21, 2021